EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Trends in the diagnosis and monitoring of barretts esophagus



Trends in the diagnosis and monitoring of barretts esophagus



Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1757



Barrett's esophagus is a premalignant mucosal change for which surveillance recommendations have been developed. Objective: To assess the changing practices in the diagnosis and monitoring of Barrett's esophagus (BE), and to determine if these changes have resulted in increased findings of dysplasia. Methods: All patients with biopsy-proven BE from 1995-2001 at a teaching hospital in British Columbia were reviewed and divided into 2 groups; Group 1: prior to publication of the 1998 American Association of Gastroenterologists guidelines on Barrett's esophagus (1995-1998), and Group 2: those undergoing endoscopies after publication (1999-2001). Endoscopies were examined for: identification of endoscopic landmarks, comment on presence/or absence of esophagitis and hiatus hernia (HH), length of BE, and quality of biopsy methods. Biopsy number was deemed adequate if more than 4 biopsies were taken every 2 cm. of endoscopically-identified BE. In patients with no endoscopic Barrett's, 3 or more biopsies was considered adequate. Patients were also followed for dysplasia. Univariate analysis was performed utilizing the chi-square and student t-test methods, SPSS version 11.0. Results: BE was biopsy-proven in 401 endoscopies (222 pts). Of these, 171 (43%) were prior to the guidelines (mean age 58 yrs, 77% male). Short-segment BE was more often diagnosed in Group 2, 49% vs. 33% (p=0.002). In assessment of biopsies, Group 2 had a greater proportion of adequate number of biopsies (44% vs. 10%), p<0.001, or 7 (CI 95% 3.8-13). In cases with no endoscopically-identified BE, Group 2 again had a higher proportion of adequate number of biopsies (85% vs. 50%), p=0.002, or 5.6 (CI 95% 1.8-17). Esophagitis was more frequently commented on in Group 2, 45% vs. 22% (p<0.001). There was no difference on comment on HH. Twenty patients were diagnosed with dysplasia (13 high-grade). There was no significant difference in the numbers of patients diagnosed with dysplasia between the groups. Conclusion: Diagnosis and monitoring for BE has improved since the publication of the1998 American Association of Gastroenterologists guidelines. There has been increased recognition of short segment BE. Despite the improvement in practices there has been no difference in the diagnosis of dysplasia.

(PDF 0-2 workdays service: $29.90)

Accession: 035985580

Download citation: RISBibTeXText



Related references

A multigene expression panel for the molecular diagnosis of Barretts esophagus and Barretts cancers. Gastroenterology 122(4 Suppl 1): A 16-A 17, April, 2002

Recurrence of columnar lined esophagus segments after surgery for Barretts associated adenocarcinoma The natural history of Barretts esophagus. Gastroenterology 118(4 Suppl 2 Part 1): A222, April, 2000

Study of p53 gene mutations and serum anti-p53 antibodies in Barretts esophagus and short segment Barretts esophagus. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1319, April, 2000

Quantitative mRNA expression analysis of multiple genes distinguish between Barretts-esophagus and Barretts-associated adenocarcinoma of the esophagus. Proceedings of the American Association for Cancer Research Annual Meeting 43: 464-465, March, 2002

The role of retinoid x receptor mrna expression in barretts esophagus and barretts associated adenocarcinoma of the esophagus. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No 501, 2003

Racial differences in the prevalence of long segment Barretts esophagus, short segment Barretts esophagus and specialized columnar epithelium at the gastroesophageal junction. Gastroenterology 110(4 SUPPL ): A79, 1996

Curative endoscopic therapy of early cancer and high grade neoplasia in barretts esophagus additional endoscopic ablation of barretts esophagus can reduce the risk of recurrent carcinomas. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No W1270, 2003

Short segment Barretts esophagus Prevalence of Helicobacter pylori infection in comparison to patients with erosive GERD, long segment Barretts esophagus as well as a asymptomatic control group A prospective evaluation. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1303, April, 2000

Trends in the epidemiology and outcome of barretts esophagus in southern europe. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No W1289, 2003

Analysis of Barretts esophagus causes and risk factors for dysplasia and drug treatment to reverse dysplasia in Barretts esophagus. American Journal of Gastroenterology 98(9 Supplement): S27, September, 2003

Ambulatory 24 hour esophageal ph monitoring in patients with barretts esophagus. Gastroenterology 100(5 PART 2): A47, 1991

Barretts esophagus Over and under-diagnosis. Gastroenterology 108(4 SUPPL ): A464, 1995

Diagnosis of barretts esophagus. DMW (Deutsche Medizinische Wochenschrift) 115(43): 1632-1635, 1990

Short and long segment Barretts esophagus 24 hour pH monitoring and esophageal manometry. Gastroenterology 110(4 SUPPL ): A180, 1996

Barretts Esophagus Problems in diagnosis and treatment. Gastroenterology. 114(4 Part 2): A141, Il 15, 1998